Tempest Therapeutics (TPST)
NASDAQ:TPST
Total Valuation
Tempest Therapeutics has a market cap or net worth of $22.81M. The enterprise value is $7.50M.
Market Cap$22.81M
Enterprise Value$7.50M
Share Statistics
Tempest Therapeutics has 14,344,034 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding14,344,034
Owned by Insiders―
Owned by Institutions1.40%
Financial Efficiency
Tempest Therapeutics’s return on equity (ROE) is -3.94 and return on invested capital (ROIC) is -179.45%.
Return on Equity (ROE)-3.94
Return on Assets (ROA)-1.55
Return on Invested Capital (ROIC)-179.45%
Return on Capital Employed (ROCE)-1.95
Revenue Per Employee0.00
Profits Per Employee-1.09M
Employee Count24
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Tempest Therapeutics is ―. Tempest Therapeutics’s PEG ratio is -0.00141.
PE Ratio―
PS Ratio0.00
PB Ratio1.79
Price to Fair Value1.79
Price to FCF-0.44
Price to Operating Cash Flow-0.14
PEG Ratio-0.00141
Income Statement
In the last 12 months, Tempest Therapeutics had revenue of 0.00 and earned -26.26M in profits. Earnings per share was -6.33.
Revenue0.00
Gross Profit0.00
Operating Income-26.57M
Pretax Income-26.26M
Net Income-26.26M
EBITDA-25.79M
Earnings Per Share (EPS)-6.33
Cash Flow
In the last 12 months, operating cash flow was -47.75M and capital expenditures 0.00, giving a free cash flow of -47.75M billion.
Operating Cash Flow-47.75M
Free Cash Flow-47.75M
Free Cash Flow per Share-3.33
Dividends & Yields
Tempest Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.85
52-Week Price Change-75.84%
50-Day Moving Average2.29
200-Day Moving Average6.11
Relative Strength Index (RSI)30.60
Average Volume (3m)50.79K
Important Dates
Tempest Therapeutics upcoming earnings date is May 7, 2026, After Close (Confirmed).
Last Earnings DateMar 30, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Tempest Therapeutics as a current ratio of 2.50, with Debt / Equity ratio of 122.09%
Current Ratio2.50
Quick Ratio2.50
Debt to Market Cap0.68
Net Debt to EBITDA-0.02
Interest Coverage Ratio-128.38
Taxes
In the past 12 months, Tempest Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Tempest Therapeutics EV to EBITDA ratio is -0.48, with an EV/FCF ratio of -0.46.
EV to Sales0.00
EV to EBITDA-0.48
EV to Free Cash Flow-0.46
EV to Operating Cash Flow-0.46
Balance Sheet
Tempest Therapeutics has $7.71M in cash and marketable securities with $8.14M in debt, giving a net cash position of -$434.00K billion.
Cash & Marketable Securities$7.71M
Total Debt$8.14M
Net Cash-$434.00K
Net Cash Per Share-$0.03
Tangible Book Value Per Share$1.61
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Tempest Therapeutics is $11.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$11.00
Price Target Upside591.82% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast49.43%